As COVID-19 mitigation measures intensify worldwide, Australian biotechnology company Hygiene Labs is supporting VIP aviation.

Global air transport has been heavily impacted by the COVID-19 pandemic.

But as vaccines are gradually introduced, and as border and travel restrictions start to ease, domestic travel is rebounding and plans are underway to create safe international travel bubbles.

One of the fastest-growing travel sectors has been VIP and private aviation, for while scheduled airlines have been forced to reduce their networks and flight frequencies, demand for executive and VIP travel has not diminished.

Major operators of corporate aircraft are reporting strong resurgence in demand, with bookings in major markets now exceeding 80 per cent of pre-pandemic levels as VIPs and business leaders, with fewer scheduled airline options, seek new ways to fly.

And their requirement for strong in-flight hygiene protocols has never been greater, with new strains of the COVID-19 virus continuing to evolve, demanding robust and continuing mitigation strategies.

Australian biotechnology company Hygiene Labs is active in aviation protection, producing a long-lasting antimicrobial shield treatment, which is verified to inactivate surface infections of Coronavirus for up to 28 days, within just one hour of application.

The treatment has been listed by Australia’s medical regulator, the Therapeutic Goods Administration, under its Hospital and Commercial Grade Surface Disinfetant categories, and has already been introduced by aviation partners including Qantas, Fiji Airways, Nauru Airlines, and Australia’s Royal Flying Doctor Service.

Now, together with its distribution partner, 145 Aviation Services, Hygiene Labs has been selected to help protect a significant VIP aircraft fleet in the Asia Pacific region.

Hygiene Labs and 145 Aviation Services are proud to support the air transport industry at all levels, in the air and on the ground, as the global effort continues to help mitigate the impact of the pandemic